ACE-031 (ACE-031 (Soluble ActRIIB-Fc Fusion))
A soluble ActRIIB-Fc fusion acting as ligand trap for myostatin, activin, and GDF-11. Removes multiple negative regulators of muscle growth simultaneously.
How it works
Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes.
Key facts
- Molecular weight: ~90,000 Da
- Half-life: 10-14 days
- Bioavailability: High (SubQ)
- Storage: Refrigerated 2-8°C. Do not freeze.
Dosing overview
- Typical dose: 0.3-3 mg/kg
- Frequency: Every 2-4 weeks
- Duration: 12-24 weeks
- Route: Subcutaneous
Reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
Possible side effects
- Epistaxis
- Gum bleeding
- Telangiectasia
- Vascular effects
- Development halted for DMD
Research
- ACE-031 in Duchenne muscular dystrophy (2019): Increased lean body mass by 5% in 12 weeks; halted due to bleeding/vascular events.
- ActRIIB decoy receptors for cancer cachexia (2021): Reversed cancer muscle wasting by 30% and improved grip strength without tumor effects.
Compare ACE-031
Community discussions about ACE-031
- Anyone see nosebleeds or gum bleeding on ACE-031? - 4 comments
- Thinking about adding GDF-11 to a low‑dose ACE‑031 stack – any thoughts on timing? - 3 comments
- ACE-031 vascular side effects, how worried should you be about the bleeding stuff? - 4 comments
- New here, trying to understand how to actually read a dosing protocol - 4 comments
- First time reading about GDF-11, can someone explain it simply? - 4 comments
- Ask the community about ACE-031
Research and educational reference only. Not medical advice.